Aion Medicines Presents Data at ObesityWeek Demonstrating Ultra-long-acting Pharmacokinetics and Pharmacodynamic Effects of AM-710, a Potential Best-in-class GLP-1 Receptor Agonist and the Longest Act

SAN FRANCISCO & ATLANTA--(BUSINESS WIRE)--Nov 4, 2025--

Aion Medicines, a subsidiary of Exavir Therapeutics, announced the presentation of preclinical data for AM-710, the company’s ultra-long-acting small molecule GLP1R agonist, at the ObesityWeek conference in Atlanta, GA demonstrating the potential for a best-in-class profile and multi-month dosing intervals.

“These impressive data demonstrate that AM-710 is a unique and highly differentiated compound in a complex and evolving landscape,” said Tim Garnett, former Chief Medical Officer of Eli Lilly and Company, and scientific advisor to Aion Medicines. “We have seen how the shift from daily to weekly incretin agents, like Wegovy and Zepbound, has transformed patient outcomes with pharmacokinetic enhancement. Aion’s next generation half